Alamar Biosciences Inc. (ALMR) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $30.60 (-10.11% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while BRKR leads on capital efficiency (1.3% ROIC).
Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 61/100 (C-) score, ALMR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($30.64) or 200D SMA ($26.98) invalidates the momentum regime and cuts Target Base ($31.01) toward Bear Floor ($24.19).
Alamar Biosciences Inc. (ALMR) dropped -10.11% to $30.60, trading at 57% of its 52-week range ($18.85 – $39.61). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Yahoo Finance Singapore report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
The study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementiasFREMONT, Calif. and HELSINKI, Finland, Nov. 02, 202
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentationsFremont, Calif., Oct. 28
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ALMR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ALMR. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Alamar Biosciences Inc. (ALMR) ranks #169 by composite RQD confidence (61/100, grade C-) and #230 by equity capitalization ($2.36B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while BRKR leads on capital efficiency and profitability with 1.3% ROIC and 45.9% gross margin. BIO currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with ALMR at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ALMR
ACTIVE
Alamar Biosciences Inc. | C- | 61/100 | — | — | — | -10.11% | $2.36B | Benchmark Subject |
| PACB Pacific Biosciences of California Inc. | D | 44/100 | — | 28.6% | -35.0% | -10.17% | $901.4M | /pacb-vs-almr → |
| CTKB Cytek Biosciences Inc. | D | 45/100 | — | 51.8% | -12.7% | -2.70% | $818.9M | /ctkb-vs-almr → |
| BRKR Bruker Corporation | C- | 59/100 | — | 45.9% | 1.3% | -7.95% | $9.45B | /brkr-vs-almr → |
| BIO Bio-Rad Laboratories Inc. | C+ | 66/100 | 13.5x | 51.9% | 0.5% | -3.18% | $10.28B | /bio-vs-almr → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alamar Biosciences Inc. (ALMR) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ALMR closed FY2025 with $140.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $140.0M | — |
As of 2026-11-02, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $30.60 (-10.11% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while BRKR leads on capital efficiency (1.3% ROIC).
Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ALMR last traded at $30.60 (-10.11% on volume of 740,095 shares), positioning the stock -0.13% below its 50-day simple moving average ($30.64) and +13.42% above its 200-day simple moving average ($26.98). Across its 52-week range of $18.85 to $39.61, ALMR sits at the 56.6% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($26.77 to $34.43).
Why ALMR Stock dropped -10.11% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
Per the Roarable RQD rating, ALMR scores 61 out of 100, a letter grade of C-, with a verdict label of "Roarable Hold — Cautious Neutral." The fundamental cash engine pillar scores 10 out of 20, reflecting ROIC of 0% and FCF yield of 0%; for a prospective investor, this means the source data shows no measurable cash return on invested capital today, so the investment case does not currently rest on earnings or cash generation. The whale and 13F flow pillar scores 16 out of 20, citing institutional accumulation and options positioning, which is the strongest pillar and suggests institutional interest is a meaningful upside driver. The insider conviction pillar scores 9 out of 20, based on SEC Form 4 and Congressional PTR cluster flow, indicating weaker insider signal support. The macro regime fit pillar scores 13 out of 20, with beta of 1.0 and sector sensitivity, meaning the stock is rated as moving in line with the broader market. The forensic balance sheet pillar scores 13 out of 20, citing Altman Z of 2.5, Piotroski F of 6 out of 9, and Debt/Equity of 0.5, which points to a moderately sound balance sheet. Valuation tradeoffs are significant: with no reported earnings-based multiples available, investors are paying for future outcomes rather than current cash flows, and the 52-week range of $18.85 to $39.61 against a price of $34.04 shows the stock has moved widely within the year. This analysis is educational and not personalized financial advice.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 (filed 2025-12-31) | $0.0M | $0.0M | $0.0M | N/A | N/A | $30.0M | N/A |
Per the SEC financials, reported revenue, operating income, and net income for FY 2025 are each $0.0M, and gross, operating, and net margins are each 0%. ROIC is 0% and FCF yield is 0% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6 out of 9, with Debt/Equity of 0.5. Reported cash is $30.0M, while debt is listed as N/A in the financials, so the balance sheet posture cannot be fully characterized from the source data.
Recent items in the news feed include a Yahoo Finance Singapore market report, a Seeking Alpha piece titled "Alamar: The Consumables Flywheel Is Just Getting Started," a Moomoo report of a 10% shareholder selling US$8.57 Million in Common Stock, a Stock Titan report that a former CEO of a cancer-detection company joined the board, a GuruFocus Q3 2026 earnings preview, and a MarketBeat report of a major shareholder selling $4,812,181.01 in stock. Per the news wire, all items carry a YELLOW light and MARKET WIRE impact label. Watch items include the reported shareholder sales, which appear in two separate news items. The Butterfly Supply-Chain Graph reports a LIQUIDITY_TAILWIND signal with a BULLISH direction and severity score of 94, a macro tailwind score of 96/100, and a 3.56x net liquidity elasticity with r = -0.18, which the graph itself frames as a rolling 5-year regression result. The graph also cites a Net Liquidity Index of $5,745.73B with a 4-week rate of change of -0.64%.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE and no butterfly links are reported. Upstream and downstream dependencies are not available in source data. Sector correlations beyond the liquidity sensitivity figure are not available in source data. The main second-order channel the source data identifies is liquidity: because the graph reports a 3.56x net liquidity beta, shifts in Fed balance sheet, Treasury General Account, and overnight RRP conditions could amplify ALMR's price moves relative to the broader market. Investors should watch whether liquidity conditions remain supportive, since the graph's bullish signal depends on them.
Real-time company headlines, analyst actions, and sector developments for Alamar Biosciences Inc. (ALMR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Moomoo report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Alamar Biosciences Inc. (ALMR) market action, institutional positioning, and fundamental catalysts.
Welcome to the ALMR (Alamar Biosciences Inc.) Roar Pit. Current RQD Composite is 61/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ALMR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Alamar Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ALMR, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $34.04 (52-wk range $18.85 - $39.61), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).